Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
07
2019
accepted:
08
09
2019
entrez:
24
10
2019
pubmed:
24
10
2019
medline:
11
3
2020
Statut:
epublish
Résumé
Prostanoids are important regulators of platelet aggregation and thrombotic arterial diseases. Their involvement in the development of portal vein thrombosis, frequent in decompensated liver cirrhosis, is still not investigated. Therefore, we used pro-thrombotic venous milieu generation by bare metal stent transjugular intrahepatic portosystemic shunt insertion, to study the role of prostanoids in decompensated liver cirrhosis. Here, 89 patients receiving transjugular intrahepatic portosystemic shunt insertion were included in the study, and baseline levels of thromboxane B2, prostaglandin D2 and prostaglandin E2 were measured in the portal and the hepatic vein. While the hepatic vein contained higher levels of thromboxane B2 than the portal vein, levels of prostaglandin E2 and D2 were higher in the portal vein (all P<0.0001). Baseline concentrations of thromboxane B2 in the portal vein were independently associated with an increase of portal hepatic venous pressure gradient during short term follow-up, as an indirect sign of thrombogenic potential (multivariable P = 0.004). Moreover, severity of liver disease was inversely correlated with portal as well as hepatic vein levels of prostaglandin D2 and E2 (all P<0.0001). Elevated portal venous thromboxane B2 concentrations are possibly associated with the extent of thrombogenic potential in patients with decompensated liver cirrhosis. ClinicalTrials.gov identifier: NCT03584204.
Sections du résumé
BACKGROUND
Prostanoids are important regulators of platelet aggregation and thrombotic arterial diseases. Their involvement in the development of portal vein thrombosis, frequent in decompensated liver cirrhosis, is still not investigated.
METHODS
Therefore, we used pro-thrombotic venous milieu generation by bare metal stent transjugular intrahepatic portosystemic shunt insertion, to study the role of prostanoids in decompensated liver cirrhosis. Here, 89 patients receiving transjugular intrahepatic portosystemic shunt insertion were included in the study, and baseline levels of thromboxane B2, prostaglandin D2 and prostaglandin E2 were measured in the portal and the hepatic vein.
RESULTS
While the hepatic vein contained higher levels of thromboxane B2 than the portal vein, levels of prostaglandin E2 and D2 were higher in the portal vein (all P<0.0001). Baseline concentrations of thromboxane B2 in the portal vein were independently associated with an increase of portal hepatic venous pressure gradient during short term follow-up, as an indirect sign of thrombogenic potential (multivariable P = 0.004). Moreover, severity of liver disease was inversely correlated with portal as well as hepatic vein levels of prostaglandin D2 and E2 (all P<0.0001).
CONCLUSIONS
Elevated portal venous thromboxane B2 concentrations are possibly associated with the extent of thrombogenic potential in patients with decompensated liver cirrhosis.
TRIAL REGISTRATION
ClinicalTrials.gov identifier: NCT03584204.
Identifiants
pubmed: 31644538
doi: 10.1371/journal.pone.0222840
pii: PONE-D-19-19236
pmc: PMC6808498
doi:
Substances chimiques
Prostaglandins
0
Banques de données
ClinicalTrials.gov
['NCT03584204']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0222840Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Hepatol. 2007 Aug;47(2):228-38
pubmed: 17573142
J Hepatol. 2007 Aug;47(2):220-7
pubmed: 17459512
J Cell Mol Med. 2012 Oct;16(10):2461-70
pubmed: 22436078
Cell Mol Immunol. 2016 May;13(3):267-76
pubmed: 27063467
J Pharmacol Exp Ther. 1984 Jan;228(1):240-4
pubmed: 6319669
Science. 2001 Nov 30;294(5548):1871-5
pubmed: 11729303
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
Thromb Res. 2015 Sep;136(3):493-503
pubmed: 26077962
J Clin Invest. 1997 Sep 1;100(5):1150-8
pubmed: 9276732
Clin Immunol. 2006 Jun;119(3):229-40
pubmed: 16540375
Hepatology. 2015 Feb;61(2):660-7
pubmed: 25284616
J Hepatol. 2012 Dec;57(6):1220-7
pubmed: 22878469
J Clin Transl Hepatol. 2017 Mar 28;5(1):50-58
pubmed: 28507927
Hepatology. 2005 Mar;41(3):579-87
pubmed: 15723448
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:375-82
pubmed: 12432930
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
Am J Physiol Gastrointest Liver Physiol. 2005 Apr;288(4):G763-70
pubmed: 15550559
Coron Artery Dis. 1994 Sep;5(9):761-5
pubmed: 7858766
Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L825-33
pubmed: 15964897
J Hepatol. 2015 Feb;62(2):332-9
pubmed: 25457205
N Engl J Med. 2011 Jul 14;365(2):147-56
pubmed: 21751907
PLoS One. 2013 Dec 26;8(12):e83341
pubmed: 24386183
Nat Med. 2014 May;20(5):518-23
pubmed: 24728410
J Hepatol. 2015 Sep;63(3):593-600
pubmed: 25872166
Thromb Haemost. 2016 Aug 1;116(2):285-99
pubmed: 27173725
Gastroenterology. 2014 Dec;147(6):1378-92
pubmed: 25173753
Liver Int. 2007 Aug;27(6):742-7
pubmed: 17617116
Hepatol Commun. 2018 Oct 05;2(12):1601-1609
pubmed: 30556044
Gastroenterology. 2007 Feb;132(2):709-19
pubmed: 17258737
Hepatology. 2015 May;61(5):1696-707
pubmed: 25644399
Nat Med. 2005 Nov;11(11):1167-9
pubmed: 16258538
Gut. 2019 Jul 3;:null
pubmed: 31270166
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
J Am Heart Assoc. 2018 Jun 23;7(13):
pubmed: 29936414
J Hepatol. 2013 Nov;59(5):1135-8
pubmed: 23742914
Eur J Gastroenterol Hepatol. 2011 Nov;23(12):1218-25
pubmed: 21971377